Pulmonary arterial hypertension (PAH) is a progressive disease leading to right-sided heart failure and poor survival (1) . In patients with PAH, 6-min walk distance (6MWD) provides an assessment of exercise capacity and, similarly to a cardiopulmonary test, independently predicts morbidity and mortality (1) (2) (3) (4) .
Because limited functional capacity profoundly influences the clinical status, changes in 6MWD have been employed as an endpoint (often primary) in clinical studies conducted for regulatory approval in patients with PAH of different etiologies treated with different drugs . However, although clinical events have generally been reported, no study has been designed to verify whether changes in 6MWD reflect changes in clinical events. Yet this information would be relevant to further assess the clinical value of 6MWD in patients with PAH.
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Therefore, purpose of this study was to verify whether improvement in 6MWD reflects incidence of clinical events in patients with PAH.
Methods
Data sources and searches. The study was designed according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement (26) . MEDLINE, Cochrane, ISI Web of Science and SCOPUS database were searched for articles published until August 2011. Study selection. Study inclusion criteria were: report of 6MWD at baseline and at end of follow-up, and of endpoints (all-cause death, hospitalization for PAH and/or lung or heart-lung transplantation, initiation of PAH rescue therapy); comparison of active drug treatment versus placebo or of different doses of active drugs; randomized protocol design. Studies were identified using the major medical subject heading "pulmonary arterial hypertension" combined with the following text and key words: 6-min walk test, 6MWD, 6-min walk test, 6-min walk distance. Data extraction and quality assessment. Two reviewers independently screened articles for fulfillment of inclusion criteria. Reviewers compared selected trials and discrepancies were resolved by consensus. Baseline characteristics, 6MWD at baseline and end of follow-up and outcomes including all-cause death, hospitalization for PAH and/or lung or heart-lung transplantation and initiation of PAH rescue therapy were abstracted. Rescue therapy was defined as interruption of blindness status of patients enrolled in clinical trials due to worsening clinical status. A composite outcome including the above clinical outcomes was calculated and the assessment of the relationship between 6MWD changes and composite outcome represented the primary objective of the study. Quality of trials was evaluated by the Detsky method (27, 28) . Publication bias was assessed using plots of study results against precision of the study (funnel plots) for each outcome. Symmetry of the funnel plots was tested using the Egger linear regression method (29), Begg and Mazumdar rank correlation method (30) , and Macaskill modified test (31) .
Of 1,583 articles identified by the initial search, 51 were retrieved for more detailed evaluation, and 22 trials were included in the study (Fig. 1) . Data synthesis and analysis. Weighted random-effects metaregression analysis was performed with the metareg command (27) (STATA version 11.0, StataCorps, College Station, Texas) to test the relationship between 6MWD changes and incidence of CE. For this analysis, the achieved differences between 6MWD changes (meters) in active treatment and control groups (⌬6MWD) were considered. For assessment of the influence of potential effect modifiers on the association between 6MWD changes and outcomes, meta-regression analyses were conducted, including the following covariates, each separately: mean age, sex, race, type of PAH, baseline functional class, 6MWD at baseline and at end of follow-up, Detsky quality score, duration of follow-up, study publication year, ⌬ mean pulmonary artery pressure, ⌬ mean pulmonary vascular resistance (⌬PVR), ⌬ mean right atrial pressure, and ⌬ mean cardiac index. For all meta-regression analyses, a random-effects model was used (27 (27, 32) . Outcome meta-analysis. Odds ratios (ORs) of the effect of randomized treatments were calculated using the metan command (STATA version 11.0, StataCorps). The choice to use OR was driven by the retrospective design of the meta-analysis based on published studies (27, 33) . Overall estimates of effect were calculated with a fixed-effects model, random-effects model, or Peto method as appropriate (27) . Statistical homogeneity was assessed using Q statistic and further quantified with the I 2 statistic. The significance level for the overall estimates of effect and for meta-regression analyses was set at p Յ 0.05. For verification of the robustness of the results, sensitivity analysis were performed to test the influence of potential effect modifiers including mean age, sex, race, type of PAH, baseline functional class, 6MWD at baseline and at end of follow-up, Detsky quality score, duration of follow-up, study publication year, ⌬ mean pulmonary artery pressure, ⌬PVR, ⌬ cardiac index, and ⌬ right atrial pressure. Finally, for assessment of the potential influence of treatments on the relationship between ⌬6MWD and outcomes, meta- regression analyses were performed for each treatment category.
Results
Characteristics of included trials. Baseline characteristics of trials included in the study are reported in (Online Fig. 2 ), and initiation of PAH rescue therapy (OR: 0.555; 95% CI: 0.347 to 0.889; comparison p ϭ 0.01, heterogeneity p ϭ 0.648) (Online Fig. 3 ). Meta-regression analysis. Meta-regression analysis showed no relationship between ⌬6MWD and composite outcome. Additionally, no relationship was found between ⌬6MWD and single components of the composite outcome (Tables 2 and 3 , Fig. 3 ). From 12 studies (5) (6) (7) 11, 13, 14, 16, 17, 19, 20, 23, 24) reporting changes in pulmonary hemodynamics (Table 4) , a significant correlation was found between ⌬6MWD and ⌬PVR (r ϭ Ϫ0.630; p ϭ 0.009). Sensitivity analysis. Results were mostly confirmed when potential effect modifiers were introduced as covariates in the meta-regression analysis. Only baseline 6MWD influenced the relationship between ⌬6MWD and hospitalization for PAH and/or lung or heart-lung transplantation with borderline statistical significance (p ϭ 0.042) ( Table 5) , whereas no significant influence was found on the composite outcome, all-cause death, or initiation of PAH rescue therapy. In the type 5 phosphodiesterase inhibitor treatment group, the relationship between ⌬6MWD and hospitalization for PAH and/or lung or heart-lung transplantation was of borderline significance (p ϭ 0.048) ( Table 2) . Publication bias. No publication bias was detected for composite or single outcome analysis.
Discussion
Improvement of 6MWD is a valuable goal in patients with PAH in whom functional capacity is severely compromised . The present study assessed whether changes in 6MWD also reflect prognosis and indicated that they do not predict reduction of major clinical events induced by therapies in a short-term follow-up (3 to 4 months). A substantial reduction of all-cause mortality, hospitalization and/or lung or heart-lung transplantation, and initiation of rescue therapy in treated patients was shown at a mean follow-up of 14.5 weeks, consistent with a recent meta-analysis for the first time reporting a favorable effect of therapies on mortality and morbidity in patients with PAH (34). However, long-term mortality remains high as reported in registry studies and emphasizes the need for longer prospective trials (35) .
6-Min Walk Distance Values
Parameters reflecting prognosis in patients with PAH would be useful for future clinical trials (1) . From our findings, changes in 6MWD do not reflect clinical event occurrence and should therefore only be considered descriptive of the effects of therapies on functional status. Notably, lack of association with 6MWD changes was found for the composite outcome and for each single component. In fact, it has been reported that threshold values of 6MWD, rather than changes induced by therapies, are prognostic predictors, with mortality higher in patients with 6MWD Ͻ Ϸ250 m and substantially lower in patients with 6MWD Ͼ440 m (4,6). Thus, despite changes induced by therapies, absolute values may remain below the high-risk threshold or improvement may occur in patients with preserved 6MWD capacity, explaining the reduced prognostic value of changes in 6MWD. Association between changes in 6MWD and clinical and hemodynamic status. Most clinical trials reporting 6MWD as primary endpoint also assessed clinical status and pulmonary hemodynamic parameters. In some of these trials (5) (6) (7) 13, 17, 20, 24) , 6MWD improvement was paralleled by improvement of hemodynamic parameters, whereas other studies (9, 11, 14, 19, 21) failed to demonstrate consensual changes in 6MWD and hemodynamic status. Interestingly, in the present study, pooling data indicated a significant inverse correlation between changes in 6MWD and changes in PVR, as previously Figure 3 Meta-Regression Analysis Meta-regression between (A) ⌬6MWD and composite outcome, (B) all-cause death, (C) hospitalization for pulmonary arterial hypertension (PAH) and/or lung or heart-lung transplantation, (D) and initiation of PAH rescue therapy. 6MWD: 6-minute walking distance
reported by Barst et al. (6) . Furthermore, 6MWD changes also did not invariably reflect the effects of treatments on clinical status, assessed by New York Heart Association functional class, Borg dyspnea index, or time to clinical worsening (9, 12, 13, 24) . Explanations for these observations can only be hypothesized. Because clinical trials do not explore pathophysiological mechanisms of endpoint changes, whether improvement of 6MWD arises from favorable resting or exercise hemodynamic changes (i.e., from mechanisms expected to have an impact on prognosis) remains unproven. Alternatively, improvement of skeletal blood flow without changes in pulmonary hemodynamics may also account for improvement of 6MWD, but no impact on prognosis would be expected in this case (36) . Therefore, studies aimed at elucidating the mechanisms of improvement in 6MWD would be much warranted to further assess the relationship between functional capacity and outcomes. Furthermore, the relatively short follow-up of clinical trials included in the meta-analysis prevented the evaluation of whether a significant association could be found at longer follow-up. Study limitations. The current meta-analysis was not patient level and therefore results should be considered provisional. Although sensitivity analysis enhanced the robustness of our findings, confirmation from a patientlevel analysis would be worthwhile. In addition, none of the studies reported clinical events as a primary endpoint and although no significant heterogeneity was found in the outcome analysis, the possibility that results may not apply to all categories of patients with PAH cannot be excluded. Finally, lack of standardization and suboptimal reproducibility of the test may also hamper the association between 6MWD changes and outcomes.
Conclusions
In patients with PAH, pharmacological treatments improved functional capacity and reduced mortality and morbidity in the short term. However, favorable effects on 
